The Claim
ROR2 kinase is required for PlexinB1 phosphorylation and downstream RhoA activation via the Sema4D-PlexinB1 signaling pathway in choroidal pericytes, and this mechanism is distinct from known pathways in other cell types, identifying ROR2 as a novel therapeutic target for neovascular AMD.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In cells of the eye called choroidal pericytes, the protein ROR2 is necessary for activating a signaling pathway involving PlexinB1 and RhoA that contributes to abnormal blood vessel growth in neovascular AMD.
See the scientific wording
The Sema4D-PlexinB1 signaling pathway in choroidal pericytes requires ROR2 kinase for PlexinB1 phosphorylation and downstream RhoA activation, a mechanism distinct from known pathways in other cell types, identifying ROR2 as a novel therapeutic target for neovascular AMD.
A signal called Sema4D from immune cells binds to a receptor called PlexinB1 on choroidal pericytes, which recruits ROR2 kinase to phosphorylate PlexinB1. This triggers RhoA to activate, causing pericytes to contract and produce stiff structural proteins. These changes destabilize blood vessels in the choroid, allowing abnormal new blood vessels to grow and leak fluid, which damages the retina.
What the research says
1 studyIn the eye, a signal called Sema4D turns on pericytes using a protein called ROR2, which causes harmful blood vessels to grow in wet AMD. Blocking this signal helps reduce those vessels, showing ROR2 could be a new drug target.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.